Amicus Therapeutics (FOLD) Shares are Up 4.17%

Amicus Therapeutics (FOLD) : Traders are bullish on Amicus Therapeutics (FOLD) as it has outperformed the S&P 500 by a wide margin of 13.84% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.72%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.17% in the last 1 week, and is up 16.67% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Amicus Therapeutics (NASDAQ:FOLD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.85 and $6.80 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.07. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.00, notching a gain of 2.64% for the day. The total traded volume was 2,244,463 . The stock had closed at $6.82 on the previous day.

The stock has recorded a 20-day Moving Average of 11.79% and the 50-Day Moving Average is 12.06%. Amicus Therapeutics, Inc. is up 8.7% in the last 3-month period. Year-to-Date the stock performance stands at -27.84%.

Amicus Therapeutics (FOLD) : The consensus price target for Amicus Therapeutics (FOLD) is $14 for the short term with a standard deviation of $3.83. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $19, however, the pessimist price target for the company is $9.


Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *